JimC
![]()
Posts:2753
In a new video, Dr. Mary Pinder reviews promising studies from ASCO 2013 on second generation ALK inhibitors LDK-378, CH5424802, and AP26113 in patients with ALK-positive advanced NSCLC, including impressive activity in crizotinib-refractory patients and those with brain mets.
You can view the video here: http://cancergrace.org/lung/2013/06/24/second-generation-alk-inhibitors/
We welcome your questions and comments here.
JimC
Forum moderator
Forums